Interventional Cardiology, 2016 (vol. 15), issue 4
Original articles
What is the optimal strategy of prehospital pretreatment of STEMI patients with P2Y12 inhibitors?
Eva Dragounová, Kristýna Junková, Roman Sviták, Milan Hromádka, Vratislav Pechman, Ondřej Sirotek, Ivo Bernat, Richard Rokyta
Interv Akut Kardiol. 2016;15(4):162-164 | DOI: 10.36290/kar.2016.032 
Experience from Pilsner region in the years 2013–2014 Prehospital pretreatment of STEMI patients with P2Y12 inhibitors remains a controversial issue also in year 2016. At the end of the year 2012, Pilsner emergency medical service in cooperation with Cardiology department, University hospital Pilsen prepared treatment protocol based on 2012 ESC guidelines for management of STEMI patients. During 2013–2014, pre-hospital P2Y12 inhibitors were administered nearly in 50 % of STEMI patients. Ticagrelor was the most frequently used drug.
Review articles
Echocardiographic predictors of aortic valve repair failure
Martin Tuna, Pavel Žáček, Miroslav Brtko, Jan Vojáček
Interv Akut Kardiol. 2016;15(4):166-171 | DOI: 10.36290/kar.2016.033
Aortic valve repairs are interventions correcting aortic regurgitation without the use of artificial heart valves. Avoiding of aortic valve replacement eliminates valve related risks but is, however, associated with uncertain long-term durability of the repair. A task for preoperative and especially intraoperative echocardiography is to detect the predictors of late failure of aortic valve repair.
Chronic thromboembolic pulmonary hypertension
Pavel Jansa, David Ambrož, Jan Kuchař, Michael Aschermann, Aleš Linhart, Jaroslav Lindner
Interv Akut Kardiol. 2016;15(4):172-176 | DOI: 10.36290/kar.2016.034
Pulmonary hypertension is a syndrome characterized by a mean pulmonary artery pressure which exceeds 25 mm Hg. Chronic thromboembolic pulmonary hypertension (CTEPH) represents its third leading cause. CTEPH is caused by both persistent thrombotic obstruction of the pulmonary arteries and peripheral vascular remodelling. As a result, pulmonary vascular resistance increases, leading to right ventricular overload and right-sided heart failure. Ventilation/perfusion lung scintigraphy is a crucial imaging modality for detecting CTEPH. CT angiography and conventional angiography along with invasive haemodynamic assessment are used for the definitive...
Coronary atherosclerosis regression - theory, facts and clinical relevance
Jan F.Vojáček
Interv Akut Kardiol. 2016;15(4):179-182 | DOI: 10.36290/kar.2016.035
Subendothelial accumulation of apo-lipoprotein B with high content of lipoproteins in the predisposed sections of the artery with diffuse intimal thickening is the main mechanism of the development of coronary atherosclerosis. A local biological response to these stored and subsequently modified lipoproteins is a chronic inflammation mediated primarily by macrophages and T cells. Lipid lowering by high intensity statin treatment leads to the stabilization of coronary plaques and reduction of the occurrences of clinical episodes of destabilisation of coronary disease. Using the newer high precision imaging techniques such as intracoronary ultrasound,...
Case reports
Feochromocytom jako neobvyklá příčina refrakterní fibrilace komor
Pavel Hajdusek, Michal Pazdernik, Jiri Kettner, Josef Kautzner
Interv Akut Kardiol. 2016;15(4):187-190 | DOI: 10.36290/kar.2016.037
Feochromocytom je vzácný neuroendokrinní nádor s výrazně variabilní klinickou manifestací a záchvatovitým průběhem. Prevalence feochomocytomu je velmi nízká a udává se přibližně u 0,1–0,6 % všech hypertoniků. Navzdory vzácnému výskytu hraje včasné stanovení diagnózy zásadní roli v další léčbě. Ta může být v některých případech životně důležitá. Typickou klinickou manifestací feochromocytomu je triáda bolestí hlavy, palpitací a zvýšeného pocení. Setrvalé komorové arytmie jsou popisovány vzácně. Přinášíme popis neobvyklého případu feochromocytomu manifestujícího se refrakterní komorovou fibrilací, která vyžadovala protrahovanou kardiopulmonální...
Catheter occlusion of pseudoaneurysm of ascending aorta after Bentall’s procedure in patient with Marfan’s syndrome
Predrag Stojadinović, Martin Wiendl, Michael Želízko, Jiří Novotný, Josef Kautzner
Interv Akut Kardiol. 2016;15(4):191-192 | DOI: 10.36290/kar.2016.038
Marfan’s syndrome (MFS) is genetic disorder of connective tissue. It was Antoine Bernard-Jean Marfan who first described disease in five-years old girl with muscular atrophy and „remarkable“ elongation of extremities. Clinically, MFS involves whole spectrum of signs. The most important clinical manifestation is dilatation of ascending aorta with possible life threatening conditions, such as dissection or rupture of the aorta, or severe regurgitation resulting in heart failure. Preventive composite valve replacement procedure is surgical gold standard. After successful aortic root replacement, there is still risk of late complications...
Case report
Rivaroxaban - 4 year experience in the treatment of deep vein thrombosis
Petr Dulíček
Interv Akut Kardiol. 2016;15(4):183-186 | DOI: 10.36290/kar.2016.036
Venous thromboembolism is a serious and frequent disease. It is dangerous not only due to the risk of fatal pulmonary embolism, but also due to the late consequences. There is a big progress in the management of the disease in recent years because of the availability of new anticoagulants. We present more than 4 years of our experience with therapy of venous thromboembolism with rivaroxaban.